SCHEMBL29456571

SCHEMBL29456571

Cc1ccc([C@H]2CCCCCN2c2cc(C)nc(N)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CRHBP P24387 2/20 0.52
CRHR2 Q13324 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.52
MAPT P10636 2/20 0.42
KDM4E B2RXH2 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
HRH3 Q9Y5N1 4/20 0.42
HRH4 Q9H3N8 1/20 0.41
GFER P55789 1/20 0.40
HSP90AA1 P07900 1/20 0.40
PDPK1 O15530 1/20 0.38
TGFBR1 P36897 1/20 0.38
AURKB Q96GD4 1/20 0.38
TSHR P16473 1/20 0.37
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36
EHMT2 Q96KQ7 1/20 0.35
NUDT1 P36639 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21516330 1.00 CRHBP (0.52) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL21516622 0.90 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL21516381 0.90 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL29456372 0.90 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL29456303 0.90 CRHBP (0.50) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL21516542 0.90 CRHBP (0.52) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL29456413 0.90 CRHBP (0.52) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL29456545 0.89 CRHBP (0.51) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL21516990 0.89 CRHBP (0.51) CRHBPCRHR2SMN1; SMN2MAPTKDM4E
SCHEMBL24313517 0.88 SMN1; SMN2 (0.48) CRHBPCRHR2SMN1; SMN2MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2025-06-12 US disclosed
US-12195453-B2 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2025-01-14 US disclosed
EP-4043460-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2024-06-05 EP disclosed
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED 2023-05-18 US disclosed
US-11440907-B1 Antiproliferation compounds and uses thereof MERCK PATENT GMBH (DE) 2022-09-13 US disclosed
EP-4043460-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2022-08-17 EP disclosed
EP-3784666-B1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2022-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195453-B2 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-11440907-B1 Antiproliferation compounds and uses thereof MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20230150993-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885
US-20250188070-A1 ANTIPROLIFERATION COMPOUNDS AND USES THEREOF MKI67, MCL1, CCNI CRHBP 4181/4885CRHR2 4068/4885SMN1; SMN2 2714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.